During the COVID-19 emergency, the Food and Drug Administration will not take action in certain circumstances against a registered outsourcing facility for compounding certain drugs to treat hospitalized patients with COVID-19; using a bulk drug substance not on the 503B bulk list; or not meeting current good manufacturing process requirements, the agency announced today.

“Many hospitals are currently experiencing difficulties accessing FDA-approved drug products used for patients with COVID-19,” the agency said. “…[I]n light of unprecedented disruptions to, and demands on, the global pharmaceutical supply chain as a result of the COVID-19 pandemic, and in order to respond to evolving regional conditions, additional flexibility is temporarily needed to ensure that treatment options are available when hospitals are unable to obtain FDA-approved drugs used for hospitalized patients with COVID-19."

Related News Articles

Blog
In this update to his September 2020 blog post, Mike Schiller, senior director of supply chain for the AHA’s Association for Health Care Resource and Materials…
Headline
The AHA today donated to UNICEF to help hospitals and communities fight a devastating surge in COVID-19 cases in India. UNICEF is rushing urgently needed…
Headline
While certain health care supply chain pressures remain, there are notable improvements, particularly in the area of collaboration, writes Mike Schiller,…
Headline
The American Medical Association yesterday announced Current Procedural Terminology codes for reporting the two-dose Novavax COVID-19 vaccine and its…
Headline
The Health Resources and Services Administration will provide nearly $1 billion to small rural hospitals, critical access hospitals and rural health clinics to…
Headline
The National Institute for Occupational Safety and Health today revoked its public health certificate of approval for Plastikon Industries’ PLASMA N95-01…